UC Berkeley's custom semiconductor spinout has now raised $125m, after Qualcomm Ventures joined existing investors such as Osage University Partners for a $65.4m series D round.
The anti-fraud technology provider, co-founded by CAE faculty, has received $50.7m in a round led by VMS Investment Group that was also backed by existing investor Legend Capital.
With the growing focus on food sustainability, University of California (UC) Santa Barbara-founded food preservative developer Apeel Science is a particularly apt selection for the Technology of the Year award.
Of the strong candidates for GUV’s Deal of the Year, Lund and Edinburgh universities-founded drug developer Galecto Biotech sealed the award for a €79m ($90m) series C close that supplemented a promising set of clinical data for its lead candidate.
Stanford-backed medical supplies delivery service Zipline has revealed two funding rounds totaling $190m, one of which is a $70m series C that included existing backer GV.
Quell Therapeutics will develop treatments for conditions such as solid organ transplant rejection and has also secured capital from UCL Technology Fund.
The series A, led by corporate venturing unit GV, may not have been last week’s largest deal, but Verve’s tie-up with fellow Harvard spinout Beam Therapeutics tells an intriguing story.
OUP and Sofinnova Partners invested in 28-7 Therapeutics to take its series A round to $82.8m, enabling the Harvard spinout to pursue accelerated development of its cancer drug pipeline.